AZN250117P71000
- 6.35
- 0.000.00%
AstraZeneca Newsroom
Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday
Berenberg Bank Keeps Their Buy Rating on AstraZeneca (AZN)
The new indication for Enhertu from Daiichi Sankyo/AstraZeneca (AZN.US) has been approved by the FDA.
On January 27, Daiichi Sankyo and AstraZeneca (AZN.US) announced that the supplemental Biological Product license application (sBLA) for Enhertu (fam-trastuzumab deruxtecan) was approved by the FDA for monotherapy in adult patients with inoperable or metastatic HER2-low expression (IHC 1+ or IHC 2+/ISH-) or HER2-ultra-low expression (IHC 0) breast cancer who have received at least one endocrine therapy in the metastatic setting.
AstraZeneca Receives FDA Approval for Enhertu Breast Cancer Treatment
AstraZeneca And Daiichi Sankyo's ENHERTU Approved In US As First HER2-directed Therapy For Patients With HER2-low Or HER2-ultralow Metastatic Breast Cancer Following Disease Progression After One Or More Endocrine Therapies
ENHERTU (Fam-trastuzumab Deruxtecan-nxki) Approved in the US as First HER2-directed Therapy for Patients With HER2-low or HER2-ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies
European Pharma Companies to Report 4Q Results With U.S Policy Uncertainty in Focus -- Sector Preview
Carnegie Group Upgrades AstraZeneca to Buy, Lifts PT
Allurion (ALUR.US) stock price surged violently; its new weight loss therapy can maintain muscle mass.
On Thursday, Allurion's stock price soared 80% in after-hours trading, following reports that the company plans to conduct clinical research combining its gastric balloon weight loss product with GLP-1 drugs.
Allurion Stock Soars 70% on Weight-loss Therapy Update
AstraZeneca to Invest C$820 Million to Move to Larger Toronto Office
Astrazeneca Announces A $570M Investment In Canada, Creating More Than 700 High-Skilled Jobs
Why Is AstraZeneca PLC (AZN) Among the Best Large-Cap Value Stocks to Buy in 2025?
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Investors Who Lost Money on AstraZeneca PLC (AZN) Should Contact Levi & Korsinsky About Pending...
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
AstraZeneca Gains NICE Nod for Lung Cancer Drugs Tagrisso and Imfinzi
Monopar Therapeutics Gains 'Buy' Rating Amid Promising Licensing Deal With AstraZeneca and Strong Growth Prospects
Leerink Partners Maintains AstraZeneca(AZN.US) With Buy Rating, Maintains Target Price $87
AstraZeneca's Strategic Positioning and Datroway Approval Drive Buy Rating Amidst Evolving Breast Cancer Treatment Landscape